{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T02:44:08Z","timestamp":1775270648272,"version":"3.50.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Individual susceptibility to valproic acid (VPA)-caused hepatotoxicity might result from genetic deficiencies in the detoxification and antioxidant enzymes including glutathione S-transferases (GSTs), catalase (CAT), superoxide dismutase (SOD), and glutathione peroxidase (GPx). This study aimed to investigate the relationships between\n                      <jats:italic toggle=\"yes\">GST mu 1<\/jats:italic>\n                      (\n                      <jats:italic toggle=\"yes\">GSTM1<\/jats:italic>\n                      ),\n                      <jats:italic toggle=\"yes\">GST theta 1<\/jats:italic>\n                      (\n                      <jats:italic toggle=\"yes\">GSTT1<\/jats:italic>\n                      ),\n                      <jats:italic toggle=\"yes\">CAT<\/jats:italic>\n                      C-262T,\n                      <jats:italic toggle=\"yes\">GPx1<\/jats:italic>\n                      Pro200Leu, and\n                      <jats:italic toggle=\"yes\">SOD2<\/jats:italic>\n                      Val16Ala polymorphisms and the risk of abnormal liver function in Chinese epileptic patients treated with VPA monotherapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      According to the levels of liver function indicators, a total of 267 epileptic patients between 1 and 65 years of age were divided into normal liver function group and abnormal liver function group.\n                      <jats:italic toggle=\"yes\">GSTM1<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">GSTT1<\/jats:italic>\n                      polymorphisms were determined using polymerase chain reaction (PCR) amplification based on the absence of a PCR amplification product.\n                      <jats:italic toggle=\"yes\">CAT<\/jats:italic>\n                      ,\n                      <jats:italic toggle=\"yes\">GPx1<\/jats:italic>\n                      , and\n                      <jats:italic toggle=\"yes\">SOD2<\/jats:italic>\n                      polymorphisms were identified using PCR-restriction fragment length polymorphism or direct automated DNA sequencing.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Carriers of\n                      <jats:italic toggle=\"yes\">CAT<\/jats:italic>\n                      had an increased risk of developing abnormal liver function compared with noncarriers in VPA-treated patients (odds ratio 3.968,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.003). Logistic regression analyses indicated that the\n                      <jats:italic toggle=\"yes\">CAT<\/jats:italic>\n                      genotype was a significant genetic risk factor for VPA-induced liver dysfunction. It suggests that individual susceptibility to VPA-induced liver dysfunction may at least partially result from genetic deficiencies in\n                      <jats:italic toggle=\"yes\">CAT<\/jats:italic>\n                      C-262T.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000574","type":"journal-article","created":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T20:04:55Z","timestamp":1542139495000},"page":"91-96","source":"Crossref","is-referenced-by-count":12,"title":["Catalase C-262T Polymorphism Is a Risk Factor for Valproic Acid\u2013Induced Abnormal Liver Function in Chinese Patients With Epilepsy"],"prefix":"10.1097","volume":"41","author":[{"given":"Linfeng","family":"Ma","sequence":"first","affiliation":[{"name":"Department of biochemistry and molecular biology, School of Life Sciences, Jilin University, Changchun, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of biochemistry and molecular biology, School of Life Sciences, Jilin University, Changchun, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of biochemistry and molecular biology, School of Life Sciences, Jilin University, Changchun, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haonan","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of biochemistry and molecular biology, School of Life Sciences, Jilin University, Changchun, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Limei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shengjing Hospital of China Medical University, Shenyang, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingjie","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of biochemistry and molecular biology, School of Life Sciences, Jilin University, Changchun, China; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0301-0082(98)00075-6","article-title":"Valproate: a reappraisal of its pharmacodynamic properties and mechanisms of action","volume":"58","author":"L\u00f6scher","year":"1999","journal-title":"Prog Neurobiol."},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.tiv.2012.01.020","article-title":"A new approach on valproic acid induced hepatotoxicity: involvement of lysosomal membrane leakiness and cellular proteolysis","volume":"26","author":"Pourahmad","year":"2012","journal-title":"Toxicol In Vitro."},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/17425255.3.3.407","article-title":"Drug metabolite profiling and elucidation of drug-induced hepatotoxicity","volume":"3","author":"Tang","year":"2007","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1080\/03602530600959433","article-title":"Oxidative stress as a mechanism of valproic acid-associated hepatotoxicity","volume":"38","author":"Chang","year":"2006","journal-title":"Drug Metab Rev."},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/toxsci\/kfq294","article-title":"Role of oxidative metabolism in the effect of valproic acid on markers of cell viability, necrosis, and oxidative stress in sandwich-cultured rat hepatocytes","volume":"118","author":"Kiang","year":"2010","journal-title":"Toxicol Sci."},{"key":"R6-20230814","first-page":"359","article-title":"Effects of sodium valproate on proliferation and apoptosis of Hep-2 cells and associated mechanism [in Chinese]","volume":"24","author":"Zhang","year":"2010","journal-title":"Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi."},{"key":"R7-20230814","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0090-9556(25)07371-4","article-title":"Conjugation of glutathione with a toxic metabolite of valproic acid, (E)-2-propyl-2,4-pentadienoic acid, catalyzed by rat hepatic glutathione-S-transferases","volume":"24","author":"Tang","year":"1996","journal-title":"Drug Metab Dispos."},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.7314\/APJCP.2013.14.6.3861","article-title":"Risk effects of GST gene polymorphisms in patients with acute myeloid leukemia: a prospective study","volume":"14","author":"Zhou","year":"2013","journal-title":"Asian Pac J Cancer Prev."},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2217\/14622416.8.5.435","article-title":"Glutathione S-transferase M1 null genotype as a risk factor for carbamazepine-induced mild hepatotoxicity","volume":"8","author":"Ueda","year":"2007","journal-title":"Pharmacogenomics."},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0009-9236(03)00014-6","article-title":"A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus","volume":"73","author":"Watanabe","year":"2003","journal-title":"Clin Pharmacol Ther."},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"e111066","DOI":"10.1371\/journal.pone.0111066","article-title":"Impact of the superoxide dismutase 2 Val16Ala polymorphism on the relationship between valproic acid exposure and elevation of \u03b3-glutamyltransferase in patients with epilepsy: a population pharmacokinetic-pharmacodynamic analysis","volume":"9","author":"Ogusu","year":"2014","journal-title":"PLoS One."},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.eplepsyres.2011.10.033","article-title":"Superoxide dismutase 2 Val16Ala polymorphism is a risk factor for the valproic acid-related elevation of serum aminotransferases","volume":"99","author":"Saruwatari","year":"2012","journal-title":"Epilepsy Res."},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/epi.12550","article-title":"ILAE official report: a practical clinical definition of epilepsy","volume":"55","author":"Fisher","year":"2014","journal-title":"Epilepsia."},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.rvsc.2007.09.009","article-title":"Assessment of the quality and quantity of genomic DNA recovered from canine blood samples by three different extraction methods","volume":"85","author":"Clements","year":"2008","journal-title":"Res Vet Sci."},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.2147\/NDT.S52585","article-title":"Possible associations between antioxidant enzyme polymorphisms and metabolic abnormalities in patients with schizophrenia","volume":"9","author":"Saruwatari","year":"2013","journal-title":"Neuropsychiatr Dis Treat."},{"key":"R16-20230814","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrd1750","article-title":"Idiosyncratic drug hepatotoxicity","volume":"4","author":"Kaplowitz","year":"2005","journal-title":"Nat Rev Drug Discov."},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1080\/10715760500306711","article-title":"Association of CAT polymorphisms with catalase activity and exposure to environmental oxidative stimuli","volume":"39","author":"Nadif","year":"2005","journal-title":"Free Radic Res."},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1158\/1055-9965.EPI-06-0104","article-title":"Associations between catalase phenotype and genotype: modification by epidemiologic factors","volume":"15","author":"Ahn","year":"2006","journal-title":"Cancer Epidemiol Biomarkers Prev."},{"key":"R19-20230814","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s004390100553","article-title":"A polymorphism in the promoter region of catalase is associated with blood pressure levels","volume":"109","author":"Jiang","year":"2001","journal-title":"Hum Genet."},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1155\/2005\/487014","article-title":"Polymorphisms in the promoter region of catalase gene and essential hypertension","volume":"21","author":"Zhou","year":"2005","journal-title":"Dis Markers."},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1034\/j.1600-0749.2002.00057.x","article-title":"Genetic association of the catalase gene (CAT) with vitiligo susceptibility","volume":"15","author":"Casp","year":"2002","journal-title":"Pigment Cell Res."},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/ahg.12152","article-title":"Association of catalase and glutathione peroxidase 1 polymorphisms with chronic hepatitis C outcome","volume":"80","author":"Sousa","year":"2016","journal-title":"Ann Hum Genet."},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1055\/s-0028-1091978","article-title":"The epidemiology of nonalcoholic fatty liver disease: a global perspective","volume":"28","author":"Lazo","year":"2008","journal-title":"Semin Liver Dis."},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"801","DOI":"10.33549\/physiolres.931377","article-title":"Modulation of antioxidant enzyme activities by sexual steroid hormones","volume":"57","author":"Pajovi\u0107","year":"2008","journal-title":"Physiol Res."},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.2337\/diabetes.53.9.2455","article-title":"Functional variants in the glutathione peroxidase-1 (GPX-1) gene are associated with increased intima-media thickness of carotid arteries and risk of macrovascular diseases in Japanese type 2 diabetic patients","volume":"53","author":"Hamanishi","year":"2004","journal-title":"Diabetes."},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/hep.23668","article-title":"Mitochondrial superoxide dismutase and glutathione peroxidase in idiosyncratic drug-induced liver injury","volume":"52","author":"Lucena","year":"2010","journal-title":"Hepatology."},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00008571-200303000-00004","article-title":"The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria","volume":"13","author":"Sutton","year":"2003","journal-title":"Pharmacogenetics."},{"key":"R28-20230814","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.cca.2007.11.035","article-title":"Glutathione-S-transferase (GST) M1 null genotype and combined GSTM1 and GSTT1 null genotypes are risk factors for increased serum gamma-glutamyltransferase in valproic acid-treated patients","volume":"389","author":"Fukushima","year":"2008","journal-title":"Clin Chim Acta."},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/bcpt.12776","article-title":"Associations of CYP2C9 and CYP2A6 polymorphisms with the concentrations of valproate and its hepatotoxin metabolites and valproate-induced hepatotoxicity","volume":"121","author":"Zhao","year":"2017","journal-title":"Basic Clin Pharmacol Toxicol."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00007691-201902000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T01:44:36Z","timestamp":1775267076000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00007691-201902000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000574","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}